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Classification of occupational asthma (OA)
A generally accepted definition proposed in an authoritative text, Asthma in the Workplace1, 
has defined OA as “ variable airflow limitation and/or airway hyperresponsiveness due to 
exposure to a specific causal agent present in a particular work environment and not to 
stimuli encountered outside the workplace.” This definition of OA does not include 
workplace activation or exacerbation of pre-existing asthma symptoms, which is called 
work-aggravated asthma. OA can be further subclassified into two different types:
1. OA appearing after an asymptomatic latent period (during which immune 
sensitization is thought to develop), including (a) IgE-associated OA typically 
triggered by high molecular weight (HMW) protein antigens, and (b) IgE-
independent OA typically triggered by low molecular weight (LMW) chemicals 
(isocyanates, red cedar dust). This type is sometimes called immunological OA.
2. OA that appears after a single, or multiple, workplace exposure(s) to non-specific 
irritants at a high concentration. The term “reactive airways dysfunction syndrome” 
cCorresponding author for proof and reprints, David I. Bernstein, MD, Departments of Internal Medicine and Environmental Health 
Sciences, University of Cincinnati College of Medicine, 3255 Eden Avenue, Cincinnati, OH 45267-0563, (513) 558-3612, (513) 
558-3799 (Fax), bernstdd@ucmail.uc.edu.
a,bCoauthors addresses: Adam V. Wisnewski, PhD, Department of Internal Medicine, Yale School of Medicine, 333 Cedar street, 
New Haven, CT 06510, (203) 432-4771, (203) 785-3229 (Fax), avw4@email.med.yale.edu
Zana L. Lummus, PhD, Department of Internal Medicine, University of Cincinnati College of Medicine, 3255 Eden Avenue, 
Cincinnati, OH 45267-0563, (513) 558-3510, (513) 558-3799 (Fax), Zana.Lummus@uc.edu
The authors have nothing to disclose
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Immunol Allergy Clin North Am. Author manuscript; available in PMC 2015 December 18.
Published in final edited form as:













or RADS has been coined to describe this type of OA. This type is sometimes 
called non-immunological OA. Since RADS is covered in detail in Chapter 7, it 
will not be covered in this chapter.
Clinical manifestations of OA
Symptoms and degree of severity
The clinical manifestations of occupational asthma are similar to those found in non-
occupational asthma, and patients present with varying degrees of disease severity. Mild 
cases may experience only episodic dry cough, chest tightness, and increased breathing 
effort at work. In more severe cases, symptoms can include wheezing, cough, chest 
tightness, shortness of breath, and dyspnea that persist away from the work environment. 
Some subjects may develop bronchitis, nocturnal awakening, or concomitant symptoms of 
rhinoconjunctivitis2.
Airway hyperresponsiveness
Nearly all asthmatics with active symptoms exhibit airway hyperresponsiveness (AHR), an 
exaggerated response to bronchoconstrictor stimuli, which can be assessed by 
pharmacologic testing (e.g., methacholine inhalation challenge) or non pharmacologic 
means (e.g., exercise challenge). In the general population, only about 50% of individuals 
with AHR have symptoms of respiratory disease3, but it does appear to be a risk factor for 
asthma, since it may precede development of asthma 4, 5. Although pre-existing airway 
hyperresponsiveness does not consistently predict development of OA caused by a 
sensitizer, a link between AHR and active symptoms of OA is firmly established,. Workers 
with OA often exhibit decreases or resolution of airway hyperresponsiveness corresponding 
with reduced or disappearance of symptoms following cessation of exposure to causative 
agents in the workplace 6.
Patterns of Asthmatic Responses
Three patterns of asthmatic response in workers with OA have been defined from decreases 
in FEV1 with time after antigen challenge during specific inhalation challenge (SIC) 
testing 7. The isolated immediate or early onset asthmatic reaction, which begins 
immediately and lasts for 1 – 2 hours is characterized by smooth muscle contraction and/or 
edema, and is not usually associated with inflammatory cells or increased airway 
hyperresponsiveness. Dual phase asthmatic responses are characterized by both an early and 
late phase bronchoconstriction interrupted by a recovery interval with the late response 
occurring 3 to 12 hours after challenge. The isolated late phase asthmatic response is almost 
always elicited by chemical sensitizers and rarely if ever associated with measurable specific 
IgE8. All late phase responses to specific sensitizers are associated with infiltration of 
eosinophils, basophils and/or neutrophils and increased airway hyperresponsiveness.
Chronic irreversible airflow obstruction observed in some workers with OA is believed to be 
associated with airway remodeling. Changes reflecting airway remodeling include loss of 
ciliated epithelial cells, increased mucus secretion by goblet cells, basement membrane 
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thickening due to subepithelial fibrosis with fibroblast and myelofibroblast activation, and 
hypertrophy of airway smooth muscle cells 6.
Workplace substances proven to be causative agents of OA
Compendia of more than 250 specific causative agents can be found in other publications or 
on special websites 9–12, and can be generally subdivided based on size, as HMW (>10,000 
Da) or LMW (<1000 Da). HMW allergens are macromolecules capable of inducing a 
specific IgE antibody response and are usually associated with workplace sensitization to 
animals, plants, and/or microorganisms. For some of the HMW agents, major and minor 
allergens have been purified, characterized and recombinantly cloned/expressed (e.g., wheat 
proteins, cow dander). Of some 189 reported HMW allergens, 56% have been confirmed by 
bronchial provocation tests.
HMW allergens that cause OA may possess functional characteristics (e.g. proteolytic 
activity) that promotes their allergenicity 13, 14. Other HMW allergens, (e.g., house dust 
mites), possess pattern recognition receptors capable of stimulating innate immune 
responses via toll receptors which may enhance their sensitizing potential 15. While most 
HMW occupational allergens are proteins, complex polysaccharides such as those contained 
in vegetable gums, may also cause OA.
Approximately 78 LMW chemicals have been described as causes of OA. Prominent LMW 
sensitizers include diisocyanates, acid anhydrides, amines, metals, therapeutic drugs, and 
reactive dyes12. Structural modeling of these chemicals suggest that certain characteristics, 
particularly the presence of two or more reactive nitrogen or oxygen containing functional 
groups, and the ability to conjugate with lysine, may be critical to OA pathogenesis 16. The 
reactive functional groups of isocyanate and other LMW asthma-causing chemicals are 
known to covalently bind to self macromolecules especially airway proteins such as human 
serum albumin, causing conformational changes, including formation of new antigenic 
determinants capable of triggering immune sensitization17.
Immune Mechanisms that Drive the Inflammatory Processes of OA
IgE mediated mechanisms
Specific IgE mediated sensitization to a workplace antigen accounts for 90% of cases of 
OA 18. In type I IgE-mediated hypersensitivity reactions, IgE antibodies bind to and cross-
link mast cell receptors, leading to degranulation and release of mediators that elicit 
asthmatic reactions in susceptible individuals. Respiratory sensitization occurs by inhalation 
of the substance, uptake by antigen presenting cells such as dendritic cells that process 
antigens and their migration to regional lymph nodes where antigen is presented to CD4+ T 
helper cells that initiate an immune response. The nature of the immune response is 
influenced by the cytokine milieu at the site of lymphocyte stimulation. Depending on host 
factors and the antigenic epitopes, helper T cells differentiate into subpopulations of effector 
cells that produce different cytokines. The two most polarized subsets are Th1 and Th2 cells. 
Interferon gamma is the principle effector cytokine produced by Th1 cells, which promotes 
isotype switching of B cells to immunoglobulin isotypes associated with phagocyte-
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dependent host reactions. Th2 cells produce three cytokines, IL-4, IL-5, and IL-13, shown to 
critically influence asthma pathogenesis in mouse models 19 and all of these are increased in 
asthmatic patients 20. IL-4 is essential for differentiation and expansion of Th2 cells, by 
upregulating the transcription factor GATA-3 in naive T cells21. IL-4 (together with IL-13) 
also promotes isotype switching from IgM to IgE production22 and promotes expression of 
both high and low affinity Fcε receptors 23. IL-5 regulates airway eosinophilia in asthma by 
promoting eosinophil differentiation, recruitment, activation and survival 24. In addition to 
promoting isotype switching to IgE, IL-13 also acts on airway epithelial cells and smooth 
muscle cells to effect airway remodeling and development of AHR 25. Despite the evidence 
linking these 3 cytokines to the pathogenesis of allergic bronchial asthma, clinical trials 
using neutralization of these cytokines for asthma immunotherapy have provided 
disappointing results 26–28. It seems probable that human asthma involves a greater variety 
of phenotypic subtypes than those discovered in mouse models. There is substantial 
evidence implicating contributions of a number of other T helper subsets, including Th9, 
Th17, Th25, as well as Th1, Th3, Tregs and iNKT cells, to inflammatory processes 
contributing to asthma aggravation and pathogenesis29.
The main feature of chronic OA caused by the prototypic LMW chemical sensitizer, toluene 
diisocyanate (TDI), is airway inflammation30. Bronchial biopsy studies in workers with TDI 
asthma reveal a mixed infiltrate of activated T cells, eosinophils, neutrophils and 
macrophages. It is noteworthy that despite the fact that specific IgE is detectable in only a 
minority of cases of diisocyanate-induced asthma (DA), the histopathologic findings are 
indistinguishable from those observed in subjects with allergic asthma31–33. Bronchial 
biopsies of workers after inhalation challenge with diisocyanates, however, failed to 
demonstrate expression of m-RNA for IgE epsilon chains and IL-4; further evidence against 
a role for IgE in this type of OA 34.
Cell mediated immune mechanisms
Alternative mechanisms have been invoked to explain chemically induced OA. Cell 
mediated immunity or delayed-type hypersensitivity has been postulated as a possible 
mechanism for isocyanate asthma; however, scientific evidence for this hypothesis is 
lacking. Anecdotal cases of concomitant contact dermatitis and OA to chemical causes of 
OA (e.g., ammonium persulfate in hair dressers) have been reported35. In addition, delayed 
patch testing responses were not identified in a study of workers with DA36. In one small 
study, hexamethylene diisocyanate (HDI)-conjugated epithelial cell proteins stimulated 
proliferation of peripheral mononuclear cells from workers with DA but not HDI-exposed 
non-asthmatic subjects37. However, in vitro lymphocyte proliferative responses to 
diisocyanate antigens have not been rigorously validated as predictors of DA.
Innate Responses
Non adaptive immune responses could play a role in chemically induced OA. Isocyanates 
may have intrinsic effects resulting in production of pro-inflammatory cytokines. For 
example, peripheral mononuclear cells challenged in vitro with diisocyanate-albumin 
conjugate antigens show enhanced release of histamine releasing factors and beta-
chemokines, particularly MCP-1 38. Furthermore, in vitro enhancement of diisocyanate-
Lummus et al. Page 4













albumin conjugate-driven MCP-1 production by blood cells was found to be strongly 
associated with DA, and served as a diagnostic marker, identifying 79% of workers with 
DA, with 91% specificity 33. Wisnewski et al demonstrated that human PBMCs stimulated 
in vitro with HDI-albumin or control albumin antigens showed marked changes in gene/
protein expression that appeared to be specific for the isocyanate moiety. Significant 
changes were noted in lysosomal genes, as well as increased expression of chemokines 
including MIF and MCP-1 which attract mononuclear cells, chitinases (pattern-recognition 
receptors) and oxidized low-density lipoprotein (CD68)39. Other investigators studied the 
gene expression profile of macrophages derived from the THP-1 human cell line and 
cultured with solubilized HDI and identified altered expression of genes involved in 
detoxification, oxidative stress, cytokine signaling, and apoptosis 40. Thus there is ample 
evidence suggesting that isocyanate chemicals stimulate non adaptive immune responses 
which contribute to respiratory sensitization, airway inflammation and clinical expression of 
OA.
Skin exposure and OA
Although the respiratory tract has been the focus of most studies on occupational asthma, 
evidence is accumulating that the skin may also play an important role in pathogenesis, as an 
exposure route for initiating immune sensitization 41–50. This hypothesis of pathogenesis is 
similar to that of the “Atopic March”, and is supported by the identification of structural 
genes as determinants of severe atopic dermatitis, a condition associated with heightened 
asthma prevalence 51–54. It is theorized that once immune sensitization occurs via the skin, 
secondary respiratory tract exposure to exceedingly low levels (which would not trigger 
responses in non-sensitized workers) elicit airway inflammation and asthma 48.
Despite being long overlooked as a potential exposure route contributing to occupational 
asthma, the skin exposure is well recognized as a mechanism for inducing immune 
sensitization, including production of allergen-specific IgE molecules 55, 56. Uptake of small 
reactive chemicals as well as large protein molecules is well documented, and thought to 
involve specific dendritic cell populations that reside in the epidermal as well as the dermal 
layers of skin 57–59. Once skin dendritic cells become activated by allergen (to express 
appropriate receptors), a chemokine gradient directs them to draining lymph nodes 60, 61. 
The outcome of skin exposure varies for different chemicals. For example, skin exposure to 
some occupational chemicals induce strong TH-2 skewed responses, while others induce 
Th-1 skewed responses 62–64. Exposure dose further influences the outcome of skin 
exposure, which may be non-linear and/or paradoxically limited at higher doses 45, 47.
Increasing recognition of the potential for occupational skin exposure to contribute to 
occupational asthma has spawned the development of animal models to further investigate 
potential pathogenic mechanisms. Several different reports have confirmed the ability of 
major occupational allergens to induce systemic immune sensitization and exacerbate 
subsequent inflammatory responses to respiratory tract inflammation in animal 
models 41, 45–47, 50. In many of these studies, skin exposure has been found to be more 
“potent” than respiratory tract exposure for eliciting primary immune sensitization, 
providing further support for an important role in disease prevention.
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While the immune system clearly plays an important role in occupational asthma, it has been 
suggested that this response is a secondary phenomenon, rather than the underlying cause of 
disease 65, 66. It is theorized that the primary defect in asthma may relate to impaired 
“barrier” function of the epithelium, which allows greater access of environmental allergens, 
microorganisms, and toxicants, which in turn trigger allergic-type inflammation 67–70. 
Impaired barrier function may be due to internal (genetic), or external (occupational 
exposure) factors that modulate the normal epithelial damage-repair cycle of the human 
airways 71. A similar process has been shown to account for certain types of allergic skin 
disease (described above), supporting the overall concept of “barrier defect”-driven 
inflammation at epithelial cell surfaces 72.
Epithelial Injury-Repair
The airway epithelium constitutes the interface between the internal milieu of the lung and 
the external environment. As the first point of contact for respirable particles, vapors and 
aerosols, it is most susceptible to their damaging effects. As mentioned above, some 
compounds that cause occupational asthma are enzymes (e.g. detergents/baking allergens) 
capable of directly disrupting cell-cell or cell-matrix interactions, while other occupational 
allergens are intrinsically cytotoxic (diisocyanates, anhydrides)13, 16, 73–75. Damage to the 
airway epithelium stimulates cell turnover through a process that involves a number of 
autocrine growth factors as well as signals from the adjacent mesenchyme 76, 77. Epidermal 
growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor–beta, and 
their corresponding receptors, have emerged as critical mediators in this process 78–80. 
Increased expression of these and other growth factors (IGF, PDGF, NGF, VEGF) is 
observed in the airway epithelium of patients with active asthma 68, 81, 82. Continuing cycles 
of epithelial-damage and repair, as might be caused by occupational exposures, may create a 
chronic wound scenario, which may increase the potential for the development of allergic 
sensitization 68, 83, 84.
The Epithelial–Mesenchymal Trophic Unit (EMTU)
Opposing layers of epithelial and mesenchymal cells constitute trophic units in which the 
resident cells counter regulate eachother’s differentiation via secreted factors 85–87. The area 
between these two cell layers contains extracellular matrix and a network of nerve fibers 85. 
Dysregulation of the EMTU, in response to specific inhaled exposures, has been 
documented in non-human primate studies and postulated to explain pathologic changes 
associated with asthma, which occur at very early stages of disease 88–90. The effects of 
specific occupational exposures on epithelial-mesenchymal interactions in vivo remain 
unstudied, however, in vitro studies suggest a possible influence on critical epithelial 
signaling components 91, 92.
Remodeling of the airway Wall
It has been postulated that when epithelial injury and repair becomes a chronic cycle, the 
structure of the airway wall may become remodeled, further increasing the opportunity for 
tissue penetration by allergens/toxins/viruses 93, 94. Structural changes observed in 
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occupational asthma include, hyalinization/thickening of the laminar reticularis, increased 
numbers of myofibroblasts, and hypertrophy/metaplasia of smooth muscle and mucus cells, 
which may persist despite cessation of exposure 95–98. In animal models, profibrotic 
cytokines, especially IL-13, mediate many of these changes 99, 100. The appearance of 
remodeling during the natural history of occupational asthma remains unclear. However, in 
patients with environmental asthma, such architectural changes occur early in the course of 
disease and may precede inflammatory changes 101, 102.
Toxicity
Many of the compounds that cause occupational asthma are cytotoxic at relatively low 
doses, including the low molecular weight chemicals, isocyanates, acid anhydrides, acrylates 
and certain metals 74, 103–105. The immune response to these compounds has generally been 
studied independent of their toxicity, however, an inter-relationship between these effects 
may exist. The “danger” signals elicited by certain occupational exposures (or co-exposures) 
may play an important role in the development of specific immune responses 106–109.
Oxidative Stress
A number of different studies provide evidence of increased oxidative stress during asthma, 
both locally within the airways, as well as systemically 110–112. Exhaled breath condensate 
and broncho-alveolar lavage samples from affected individuals have been shown to contain 
increased levels of 8-isoprostane, and other well established maker of oxidative 
stress 113, 114. Peripherally, additional biomarkers of oxidative stress (superoxide anion 
generation, lipid peroxidation, total nitrates/nitrites, total protein carbonyls, and total protein 
sulfhydrils) may be increased, concomitant with decreased levels of specific anti-oxidants 
(superoxide dismutase, catalase activity, glutathione, and glutathione peroxidase activity, 
etc) 112, 115, 116. It remains unclear if increased levels of oxidative stress observed in 
asthmatic individuals is a cause of disease, or rather a result of ongoing inflammation in the 
airways, which itself produces reactive oxygen species. Regardless of the source, oxidative 
stress is thought to aggravate asthmatic airway inflammation via multiple mechanisms, 
including pro-inflammatory mediators, and effects on smooth muscle and mucus 
secretion 117–119.
The molecular mechanisms by which oxidative stress effect cellular responses are beginning 
to be deciphered. At low levels of oxidative stress, the transcription factor Nrf2 is released to 
the nucleus where it induces expression of >200 genes with anti-oxidant response elements 
in their promoters 120. When oxidative stress exceeds the protective capacity of Nrf2-
induced genes, additional intracellular cascades (MAPK, NF-kB) may be triggered, leading 
eventually to the expression of pro-inflammatory cytokines, chemokines and adhesion 
molecules 117, 121.
Certain exposures (diesel exhaust, ozone) are well-recognized for their ability to induce 
oxidative stress, and have been shown to act as adjuvants for the development of allergic-
type respiratory responses in animal models 122–126. Recent studies suggest that other 
important occupational exposures (isocyanates, chlorobenzene, cerium and silicon oxide 
constituents of nanoparticles) may also induce oxidative stress 74, 127–131.
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Thiols, especially glutathione, play a major role in protecting the airway against oxidant 
damage 132, 133. Airway fluid thiol levels are normally maintained at high levels (>100 uM), 
greater than 10-fold above systemic blood levels, and are intimately connected to redox-
sensitive (pro-inflammatory) intracellular signaling cascades 134. In vivo animal models, and 
in vitro studies with human cells have demonstrated that isocyanate chemicals have marked 
effects on airway thiols 135, 136. Glutathione may be an especially critical target as its levels 
are known to modulate TH-1 vs. TH-2 priming by dendritic cells, and subsequent asthmatic 
response in animal models 137, 138. Human genetic studies that associate glutathione-
dependent enzymes polymorphisms (GST-P1, GST-M) with occupational and 
environmental asthma further support a potentially important role for airway thiols in 
asthma pathogenesis 139, 140.
Neurogenic inflammation
The airway wall is entwined with fibers from neurons, some of which penetrate the 
basement membrane, reaching into the epithelial cell layer, where they sense external 
signals via specific receptors, and secrete factors capable of eliciting inflammation and 
bronchoconstriction 141. Critical mediators include the neuropeptides, substance P (SP), 
neurokinins (NK), calcitonin gene-related and vasoactive intestinal peptides (GCRP and 
VIP), which trigger responses from immune, vascular and smooth muscle cells via specific 
receptors 142–144. Further cross-talk between neuronal and immune cells may be modulated 
through the epithelial-derived enzyme, NEP, which breaks down pro-inflammatory 
neuropeptides 145. Epithelial NEP activity can be further affected by occupational and/or 
environmental exposures 146, 147. Thus, neuronal cells produce potent mediators that may 
interact with other cell types to influence exposure-induced asthmatic responses.
A single neuronal receptor, TRPA1, which recognizes a wide variety of “noxious” stimuli, 
including occupational allergens (diisocyanates), environmental irritants (cigarette smoke, 
cholrine), and endogenous compounds (reactive oxygen/nitrogen species, arachodonic acid 
derivatives) has now been molecular cloned 148, 149. In animal studies, TRPA1 expression 
co-localizes with SP, NK, and GCRP in nerve fibers in the airways, and TRPA1 knockout 
mice exhibit reduced inflammation in an ovalbumin asthma model 150, 151. However, 
species differences in TRPA1 activation, as well as general innervation of the lung, are well 
noted, limiting translation of animal studies on airway neuroinflammation to human 
asthma 141, 152.
Genetic susceptibility factors for OA
OA syndromes, like non-occupational asthma, are likely polygenic disorders. Identification 
of specific genes that contribute to OA has been challenging because study populations are 
relatively smaller than those needed for genetic association studies. Genetic studies in OA to 
date can be categorized as: those associated with immunoregulation and innate immunity; 
those associated with Th2 immunity; and anti-oxidant enzyme genes.
Lummus et al. Page 8













Genes Associated with immunoregulation and innate immunity
Candidate gene studies have been reported investigating associations between HLA Class II 
alleles or haplotypes and isocyanate induced OA. Bignon et al evaluated HLA class II 
DQA1, DQB1, DPB1, and DRB alleles and reported that confirmed DA was associated with 
DQB1*0503 and the allelic combination DQB1*0201/0301. The DQB1*0501 allele and the 
DQA1*0101-DQB1*0501-DR1 haplotype appeared to be protective as these were increased 
among healthy exposed controls and decreased in DA 153. These findings were confirmed in 
a second study 154. A single amino acid substitutions at residue 57 of aspartic acid in DQB1 
* 0503 was significantly increased in DA workers and negatively associated with a valine 
substitution at DQB1 * 0501155. However, these findings were not reproducible in a smaller 
US study, a European study of DA or a similar Korean study156, 157. In the latter Korean 
study, HLA DRB1*1501-DQB1*0602-DPB1*0501 haplotype was significantly increased in 
84 workers with TDI asthma compared with two asymptomatic comparator groups 157.
HLA associations have been identified with other chemical causes of OA. A higher 
frequency of HLA DQB1*0603 and DQB1*0302 alleles and a reduced frequency of the 
DQB1*0501 allele has been reported in western red cedar sawmill workers with DA when 
compared with healthy workers 158. Among chemical workers exposed to acid anhydride 
chemical sensitizers, HLA class II allele DQB1(*)0501 within DQ5 HLA was associated 
with specific IgE to at least one acid anhydride (AA) antigen 159.
Among 335 laboratory animal workers were genotyped for TLR4/8551 and TLR4/8851 
single nucleotide polymorphism (SNP) variants and workers with the TLR4 8851 G variant 
has reduced responsiveness to inhalation of endotoxin and were at higher risk for atopy and 
sensitization to laboratory animal allergens 160.
Th2 gene markers
Th2 cytokine gene polymorphisms of IL4 receptor alpha (IL4RA) and IL13 have been 
associated with allergic asthma and/or allergic sensitization 161. A candidate gene study was 
performed in 103 isocyanate exposed workers with DA confirmed by a positive SIC test, 
115 symptomatic workers with negative SIC tests, and 150 asymptomatic spray painters 
exposed to HDI. DNA was extracted and workers were genotyped for IL4RA (I50V), 
IL4RA (Q551R), IL4RA (E375A), IL13 (R110Q), and CD14 (C159T) SNPs. The 
interactions between diisocyanate exposure (HDI vs. MDI, TDI) and specific genotype 
combinations (i.e., IL4RA II + IL13 RR; IL4RA II + CD14 CT; and IL4RA II + IL13 RR + 
CD14 CT) were significantly associated with DA compared with SIC negative workers. 
When comparing HDI-exposed workers with DA (n=50) and a different comparator group 
of asymptomatic HDI-exposed workers (n = 150), the association between DA and the 
IL4RA II + CD14 CT and IL4RA II + IL13 RR + CD14 CT genotype combinations trended 
toward statistical significance (P <.10) after adjustment for relevant confounding 
variables161–163.
Anti-oxidant enzyme genes
Gene SNPs associated with the Mu (M), Theta (T), and Pi (P) classes of the glutathione-s-
transferase (GST) isoenzyme superfamily have been studied as predictors of DA. There is 
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good rationale to explore GST genotype variants in that GST has been shown to modify 
biotransformation of isocyanates and excretion of metabolic products 164. Reduced 
glutathione directly inhibits in vitro binding of diisocyanates with albumin 165. Deletion of 
the GSTM1 gene (null genotype) has been associated with a two-fold increased risk of 
diisocyanate-induced asthma140. The GSTP1 Val/Val homozygous genotype was lower in 
DA suggesting a protective modifying effect (OR, 0.23; P =.074)139.
Genome wide association studies have not been performed extensively in OA. Recently 
groups of Korean workers including 84 with TDI asthma and 263 unexposed controls 
underwent genotyping with GeneChip arrays consisting of 500,000 SNPs166. Several SNPs 
of the alpha-T-catenin (CTNNA3) gene were identified to be significantly associated with 
DA. Alpha-T-catenin is a molecule involved in E-cadherin mediated cellular adhesion. The 
significance of this finding is unknown.
Summary
Occupational asthma is one of the most common forms of work-related lung disease in all 
industrialized nations. The clinical management of patients with OA depends on an 
understanding of the multifactorial pathogenetic mechanisms that can contribute to this 
disease. Once established, the clinical manifestations of OA are similar to those found in 
non-occupational adult asthma, but the unique relationship of OA to a specific workplace 
antigen offers the possibility of successful therapy by early diagnosis and cessation of 
exposure to the causative agent. Specific IgE-mediated sensitization to high molecular 
weight antigens accounts accounts for 90 percent of cases of OA. Low molecular weight 
chemical sensitizers have generally not been found to cause OA by an IgE-mediated 
mechanism. Numerous factors have been found to contribute to the pathogenesis of 
chemically-induced OA, including innate immune mechanisms, and non-immunological 
mechanisms of epithelial injury, airway remodeling, oxidative stress, neurogenic 
inflammation, and genetic risk factors. Genes found to be associated with increased 
susceptibility to OA include HLA class II genes, and genes associated with innate immunity, 
Th2 immunity, and anti-oxidant enzyme genes.
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